MBX Biosciences, Inc. (MBX)

MBX Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-86.97	-61.92	-32.56	-26.14
Depreciation & Amortization	0.25	0.24	0.16	0.06
Stock-Based Compensation	8.68	5.22	2.04	0.31
Other Adjustments	-3.48	-2.82	-0.88	1.36
Changes in Accounts Payable	-2.46	3.93	0.41	0.67
Changes in Accrued Expenses	6.8	3.17	0.05	1.45
Changes in Other Operating Activities	-2.77	-2.5	-1.19	-0.83
Operating Cash Flow	-79.95	-54.68	-31.98	-23.12
Capital Expenditures	-1.93	-0.87	-0.13	-0.44
Purchases of Investments	-358.15	-239.47	-63.8	-20.22
Proceeds from Sale of Investments	276.37	79.75	33	9.25
Investing Cash Flow	-83.71	-160.6	-30.93	-11.41
Long-Term Debt Issued	-	-	-	10
Net Long-Term Debt Issued (Repaid)	-	-	-	10
Issuance of Common Stock	190.36	174.95	0.74	0.03
Net Common Stock Issued (Repurchased)	190.36	174.95	0.74	0.03
Issuance of Preferred Stock	-	63.5	68.51	36.49
Net Preferred Stock Issued (Repurchased)	-	63.5	68.51	36.49
Other Financing Activities	-0.77	-4.34	-0.03	-0.46
Financing Cash Flow	189.59	234.1	69.22	46.06
Net Cash Flow	25.94	18.83	6.31	11.53
Free Cash Flow	-81.88	-55.56	-32.11	-23.56
Free Cash Flow Per Share	-2.24	-5.22	-31.52	-35.33
Levered Free Cash Flow	-87.08	-57.96	-33.27	-15.23
Unlevered Free Cash Flow	-98.16	-64.23	-36.02	-24.26

Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q